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Abstract Carbonic anhydrase II (CA II) generates bicarbonate 
in human pancreatic duct cells. We have developed the human 
pancreatic duct cell line DANG as a model to study the effects 
of all-trans-retinoic acid (ATRA) on CA II gene expression. 
ATRA treatment resulted in a time- and dose-dependent inhibi- 
tion of CA II mRNA concentrations in DANG cells. These inhib- 
itory effects were paralleled by a time-dependent decrease of CA 
II protein concentrations. Nuclear run on analysis revealed that 
the decrease of CA II mRNA concentrations was due to a de- 
creased rate of CA II gene transcription. These data show that 
ATRA transcriptionally modulates CA II gene expression in 
human pancreatic arcinoma cells. 
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I. Introduction 
The carbonic anhydrase gene family (CA, EC 4.2.1.1) is en- 
coded by at least seven genes, designated CA I-VII, which are 
characterized by tissue-specific expression and varying physio- 
logical functions [1]. In general, this enzyme family catalyzes 
the interconversion of carbon dioxide and water to bicarbonate 
and protons [2]. In the mammalian ontransformed pancreas, 
CA II is the predominant isozyme which is exclusively ex- 
pressed in the exocrine ductal cells. CA II thus provides bicar- 
bonate anions required for the elaboration of the bicarbonate- 
rich pancreatic secretion, which is essential to neutralize the 
acidic milieu [3,4]. It is currently unclear, whether this cell 
type-specific expression of CA II is maintained uring the ma- 
lignant transformation of the exocrine duct cell. Furthermore, 
although CA II plays a critical role in duct cell specific function, 
very little is currently known regarding the regulation of CA 
II gene expression in human pancreatic tumor cells. To address 
this problem we have recently developed an in vitro system 
using human pancreatic ductal tumor cell lines [5]. Using this 
in vitro model, we previously found that the vitamin A deriva- 
tive all-trans-retinoic acid (ATRA) exerts profound effects on 
the cell biology of ductal tumor cells, which is mainly character- 
ized by a profound inhibition of anchorage-dependent and 
-independent growth [5]. Because this observation bears impor- 
tant therapeutical implications, we were therefore interested to 
further investigate the effects of ATRA on ductal specific cell 
function, using CA II gene expression as a representative 
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model. We now present evidence that CA II is expressed in 
human malignant pancreatic ductal cells in vivo and in vitro; 
furthermore, CA II is transcriptionally downregulated by 
ATRA in the human pancreatic arcinoma cell line DANG.  
2. Materials and methods 
2.1. Cell culture 
DANG cells were grown in DMEM medium supplemented with 10% 
charcoal stripped fetal calf serum. Cells were kept under 95% air and 
5% CO2 at 37°C. ATRA was added from stock solutions, prepared 
under subdued light. Control vehicles received ethanol, and the final 
concentration of ethanol in the medium did not exceed 0.1%. 
2.2. Northern blots 
RNA was isolated by the guanidinium isothyanate procedure [6]. 
RNA was denatured by formaldehyde, subjected to elctrophoresis 
through a 1% agarose gel in the presence of formaldehyde and then 
transferred onto nitrocellulose. Prehybridisation, hybridisation and 
washing procedures were carried out exactly as previously described [7], 
using a random primed cDNA probe for human CA II [8]. All filters 
were then sequentially hybridised with a cDNA encoding human fl- 
actin. Repeated quantitative analysis was performed by slot-blotting 
[7]. The hybridisation signal was quantitated by laser densitometry, 
normalised to fl-actin and then expressed as % of control. 
2.3. Nuclear run on analysis 
Nuclei were isolated by sucrose gradient centrifugation. RNA prod- 
ucts were purified using deoxyribonuclease, proteinase K, and salt 
precipitation according to the procedure of Nelson and Groudine [9]. 
Care was taken that each experimental condition contained the same 
amount of nuclei and radioactivity. Prehybridisation, hybridisation and 
washing procedures were carried out exactly as previously described [7]. 
2.4. Western blots 
Cell lysates were prepared by freeze-thawing cells in phosphate-buff- 
ered saline and pelleting the debris. 50/.tg protein per lane were run on 
SDS gels, transferred to a nylon membrane [10] and probed with rabbit 
anti-human CA II antibody followed by goat anti-rabbit IgG conju- 
gated to alkaline phosphatase. Blots were developed with nitroblue 
tetrazolium and bromochloroindoyl phosphate [11]. The detected sig- 
nal was then quantitated by laser densitometry. 
2.5. In situ hybridisation 
Surgical samples of human pancreatic adenocarcinomas were fixed 
in 10% neutral formalin and embedded in paraffin. Sections of 4/tm 
were cut from specimen blocks using a microtome. The human CA II 
cDNA was subcloned into pRC/CMV vector in either orientation with 
respect o the T7 promotor site in order to transcribe antisense and 
sense RNA probes. Digoxigenin-labeled cRNA probes were generated 
exactly as previously described [12], using identical hybridisation condi- 
tions. The immunodetection was carried out using a sheep anti-digoxi- 
genin antibody followed by a colour reaction in a chromogen solution 
[121. 
2.6. Statistics 
Statistical analyses were performed using the Student's t-test. Differ- 
ences were considered to be significant at P < 0.05. All data are given 
as mean + S.E.M. 
All rights reserved. 
3. Results MW (k~ 
3.1. CA H expression in malignant pancreatic ductal cells 
To verify that CA II gene expression remains preserved ur- 
ing malignant transformation we performed non radioactive in 
situ hybridisation on 5 independent surgical resected specimens 
of human pancreatic adenocarcinomas (Fig. 1). In all tumors 
examined, we observed a homogenous expression of CA II 
mRNA molecules restricted to the malignant transformed duc- 
tal cells. In contrast, no specific hybridisation signal was ob- 
served either in the surrounding connective tissue nor in the 
negative (sense) control (Fig. 1). 
3.2. ATRA inhibits CA H gene expression in human DANG cells 
Having confirmed the expression of CA II in human pancre- 
atic carcinoma, we next investigated the effects of ATRA on 
CA II expression in the human pancreatic carcinoma cell line 
DANG. Western blotting revealed the expression of a 29 kDa 
CA II protein which is in good agreement to what has previ- 
ously been described [13]. Incubation of DANG cells with 
ATRA (10/.tM) resulted in a time-dependent decrease of CA 
II protein concentration with a maximal inhibition occuring 
after 96 h of ATRA treatment (18 + 6% of control, n - -4 ,  
P < 0.05) (Fig. 2). To further investigate the underlying mecha- 
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Fig. 2. Effects of ATRA on CA II expression in DANG cells. Shown 
is a representative Western blot (a) and the statistical analysis of 
4 independent experiments (b) (*P < 0.05). 
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Fig. 1. In situ hybridisation ofCA I1 in human pancreatic carcinoma. 
Shown is the intense staining of the centrally located uctular tumor 
cells, while the surrounding connective tissue as well as the negative 
control (sense) show no specific staining. Shown is a representative of
5 independent tumors analysed. 
nisms responsible for CA II inhibition by all-trans-retinoic acid, 
we next analysed the effects of ATRA on CA II mRNA concen- 
trations. Using a cloned human cDNA for CA II in Northern 
blotting we detected a single mRNA species of 2.0 kb in DANG 
cells (Fig. 3a). Incubation of DANG cells with ATRA resulted 
in a time-dependent decrease of CA II mRNA concentrations, 
while/~-actin mRNA levels which served as an internal control, 
did not change under any experimental condition (Fig. 3a). 
Again, maximal inhibition was observed after 96 h of ATRA 
incubation (20 + 5% of control, n = 3, P < 0.05) (Fig. 3b). Ex- 
tending the ATRA incubation beyond 96 h did not result in a 
further decrease of CA II mRNA concentrations (data not 
shown). The effects of ATRA on CA II gene expression were 
dose-dependent with half-maximal effects observed at 50 nM 
and maximal effects observed at 10/IM of ATRA (21 _+ 4% of 
control, n = 4, P < 0.05) (Fig. 4). Testing a variety of synthetic 
and natural retinoids in terms of their biological potency to 
inhibit CA II gene expression we observed the following gradi- 
ent: all-trans-RA = 13-cis-RA > 9-cis-RA > AM80 > AM 580 
(data not shown). 
3.3. Effects o f  ATRA on CA H gene transcription 
We then examined whether the effects of ATRA on CA II 
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Fig. 3. Effects of ATRA on CA II mRNA concentrations in DANG 
cells. Shown is a representative Northern blot experiment (a) and the 
statistical nalysis of 3 independent experiments (b) (*P < 0.05). 
gene expression were due to a decreased rate of CA II gene 
transcription. Using the nuclear run on technique in control 
nuclei and nuclei which had been pretreated with ATRA for 48 
h we repeatedly observed a decreased hybridisation signal for 
CA II in the ATRA pretreated cells (Fig. 5). Densitometric 
analysis revealed a CA II transcription rate of 23 + 8% of 
control (n = 3) after ATRA preincubation for 48 h. These in- 
hibitory effects were specific for CA I! because fl-actin gene 
transcription was not altered by ATRA under any experimental 
condition (Fig. 5). The specificity of the hybridisation signal 
was confirmed by including the RNA polymerase II inhibitor 
~-amanitin one aliquot of nuclei, which completely abolished 
the hybridisation signal (data not shown). 
characteristics [17], there is however currently no information 
available whether the expression of CA II is maintained during 
malignant transformation f the human pancreatic duct cell. By 
using a non radioactive in situ hybridisation technique we 
found a homogenous and duct cell restricted expression of CA 
II mRNA transcripts in all human pancreatic carcinomas ex- 
amined. In accordance to the nontransformed pancreas, CA II 
was not expressed in acinar, endocrine or mesenchymal cells. 
This observation suggests, that although highly dedifferen- 
tiated, human pancreatic arcinomas maintain the expression 
of the duct cell specific protein CA II during malignant trans- 
formation. In analogy to the in vivo data, we also demonstrated 
the expression of CA II mRNA and protein in the human 
pancreatic arcinoma cell line DANG; this cell line should 
therefore serve as a useful model to study the effects of ATRA 
on malignant duct cell biology. The pleiotropic effects of reti- 
noids are mediated by two families of nuclear eceptors, desig- 
nated retinoic acid receptors (RAR) and retinoid X receptors 
(RXR) each consisting of three receptor subtypes, named ~, fl 
and y (reviewed in [18,19]). Both, RAR and RXR act as ligand- 
activated transcription factors, controlling ene transcription 
initiated from promotors of retinoid regulated genes by inter- 
acting with cis-acting elements, the so-called RAREs (retinoic 
acid-responsive elements) [18,19]. We have previously shown by 
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4. Discussion 
We have previously shown that all-trans-retinoic acid inhibits 
growth in the human pancreatic carcinoma cell line DANG [5]. 
This observation might bear important clinical implications in 
terms of developing new experimental strategies for the treat- 
ment of pancreatic carcinoma. Based on these observations we 
were interested to gain further insights into the effects of ATRA 
on duct cell specific functions. CA II, by catalyzing the hydra- 
tion of carbon dioxide, is essential for the bicarbonate produc- 
tion by pancreatic duct cells and therefore represents a central 
duct cell specific functional molecule. The duct cell restricted 
expression of CA II has been demonstrated in the nontrans- 
formed pancreas of the mouse, guinea pig and human [14-16]. 
Given that pancreatic arcinomas very often display a highly 
dedifferentiated phenotype with a frequent loss of duct cell 
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Fig. 4. Dose-dependent effects of ATRA on CA II gene expression. For 
these xperiments DANG cells were incubated with the indicated doses 
of ATRA for 96 h. Shown is a representative slot-blot experiment (a) 
and the statistical analyses of 4 independent experiments (b) 
(*P < 0.05). 
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Fig. 5. Effects of ATRA on CA II gene transcription i  DANG cells. 
DANG cells were incubated with 10/tM ATRA or vehicle for 48 h and 
CA II and fl-actin transcription were assessed by nuclear run on assays. 
Duplicate slots for each cDNA were hybridised to ensure the reproduc- 
ibility. Shown is a representative of 3 independent experiments yielding 
nearly identical results. 
reverse-transcriptase PCR that the human DANG cell line does 
express all RAR and RXR subtypes except for the RXRg [5]. 
It was therefore of great interest how ATRA, besides the inhi- 
bition of growth, would interfere with tumor duct cell specific 
function. We observed a specific, time- and dose-dependent 
decrease of CA II expression in DANG cells as a consequence 
of ATRA incubation. This decrease of CA II protein was quan- 
titatively completely explained by a time-dependent decrease of 
CA II mRNA concentrations, indicating that the effects of 
ATRA are mainly located at a pretranslational level. Further- 
more, the time course of CA II inhibition is in excellent agree- 
ment with the previously observed antiproliferative effects of 
ATRA on DANG cells [5]. Although most of the biological 
effects of retinoids are believed to occur via transcriptional gene 
regulation, stabilization of mRNA transcripts and posttransla- 
tional stabilization of the protein product by retinoids have 
previously been described [20,21]. To address this question we 
performed nuclear un on experiments; CA II gene transcrip- 
tion after 48 h ATRA treatment was reduced to 23 + 8% of 
control, which was nearly identical to the CA II mRNA con- 
centrations observed at the same time (27 _+ 11% of control). 
Therefore a decrease in CA lI gene transcription is predomi- 
nantely if not exclusively, responsible for the inhibition of CA 
II expression in DANG cells. Although the promotor egion of 
the human CA II gene has been cloned and sequenced [22], very 
few physiological or pharmacological substances have been 
identified that regulate CA II gene expression. In this context 
it is of interest, that another member of the steroid hormone 
superfamily, 1,25-dihydroxyvitamin D 3,exerts opposite ffects 
on CA II gene expression in an osteoclast cell line, character- 
i sed by an increase of CA I I gene expression [l 3]. The availabil- 
ity of the promotor region of CA II will now enable us to 
directly characterize the regulatory sequences responsible for 
the retinoid mediated inhibition of CA II gene expression in 
DANG cells. 
In summary, we have shown that CA II expression is main- 
tained during malignant transformation of human pancreatic 
duct cells. Furthermore, we have established the DANG cell 
line as a valid in vitro model to investigate the effects of reti- 
noids on tumor duct cell function. The observed inhibition of 
CA II gene transcription during ATRA mediated inhibition of 
growth needs to be considered when evaluating ATRA as a 
therapeutical pproach for the treatment of human pancreatic 
cancer. 
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